MarketLens
Sign Up

What's Behind the Recent Insider Selling at AnaptysBio

7 months ago
SHARE THIS ON:

What's Behind the Recent Insider Selling at AnaptysBio

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Anaptys Announces Participation in Upcoming Investor Conferences

AnaptysBio said its executive team will participate in multiple upcoming investor conferences, with no dates, locations, or webcast details disclosed in the announcement.
Stock News•1 months ago

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Inhibrx Biosciences CEO bought over $3.6M of INBX shares after a clinical outperformance selloff, with ~28% of float short and an FDA approval date pending. The stock closed at $97.93, down 2.15% on 1...
Stock News•3 months ago

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio's value now hinges on Jemperli royalties from GSK, with a 95% targeted EBIT margin and over $140M net cash. Royalty retention will rise after the Sagard obligation is paid by mid-2027.

Breaking News

View All →

Top Headlines

View More →
Stock News•20 minutes ago

Microsoft had rallied back to record highs. Then came the election and Outlook outage

Stock News•34 minutes ago

Palo Alto Networks (PANW) Q1 Earnings and Revenues Top Estimates

Stock News•35 minutes ago

Elon Musk says ousting Jensen Huang is like ‘kicking Michael Jordan off your team'

Stock News•43 minutes ago

Nvidia Q3: Hasn't Been This Cheap In A Decade

Stock News•46 minutes ago

Palo Alto Networks: Accelerating Growth and a $4.5 Billion Bet on the Future of Cybersecurity